Glaukos Stock Drops Over 13% Amid Insider Sale Despite Positive Trial Data
Despite positive results from a late-stage trial for its Epioxa eye therapy, Glaukos Corporation (GKOS) experienced over a 13% drop in stock price on Thursday. The decline occurred amid an insider sale by the company’s chief development officer, Tomas Navratil. The market reaction highlights investor sensitivity to insider selling activities even when accompanied by positive clinical data. A regulatory filing confirmed the transaction, raising concerns about potential internal confidence or strategic shifts within the firm.
Tickers: $GKOS
Topics: clinical trial results insider selling stock price drop